Audit Finds MDMA and Psilocybin Trials Rarely Test TRIM Hypothesis 3 at 12 Months

Most MDMA and Psilocybin Trials Do Not Rigorously Test TRIM Hypothesis 3

A systematic evidence audit published on November 5, 2026 (OpenAlex W7225294160) finds that the majority of randomized controlled trials (RCTs) of MDMA- and psilocybin-assisted therapy have not rigorously tested Hypothesis 3 of the Trauma-Resilience Integration Model (TRIM). Hypothesis 3 specifies that, to demonstrate superiority, psychedelic-assisted therapy must outperform a traditional-therapy comparator on a validated symptom scale, with this advantage persisting at 12 months. The audit, led by Krieger (manuscript submitted to Psychological Trauma: Theory, Research, Practice, and Policy, November 2026), systematically scored all eligible published trials against three criteria: comparator type, outcome scale, and duration of controlled follow-up.

This approach does not generate new efficacy data or meta-analyze existing results. Instead, it clarifies whether the current evidence base is sufficient for claims about the long-term, comparative effectiveness of psychedelic-assisted therapy versus established treatments.

Mechanism and Context: What the Audit Examined

The audit's methodology involved reviewing all published RCTs of MDMA- and psilocybin-assisted therapy, focusing on three core elements required by TRIM Hypothesis 3:

• Comparator Type: The trial must include a traditional therapy comparator arm, not just placebo or waitlist controls.
• Outcome Scale: The trial must use a validated symptom scale relevant to the disorder being treated.
• Controlled Follow-Up Duration: The trial must report outcomes at 12 months or longer, with the comparator arm still in place.

According to the audit, while several trials meet one or two of these criteria, very few—if any—meet all three simultaneously. Most notably, the longest controlled follow-up periods in the literature are often shorter than 12 months, or the comparator arms are not active traditional therapies. For example, the pivotal Phase 3 MDMA-PTSD trials (NCT03537014; MAPS PBC, now Lykos Therapeutics) used placebo with therapy as a comparator, but their longest controlled follow-up was six months. Similarly, leading psilocybin trials for depression (e.g., NCT03775200, COMPASS Pathways) often compare to placebo or waitlist, not to established psychotherapies, and rarely extend controlled follow-up to a full year.

Policy and Research Implications: Evidence Gaps for Durability and Comparative Value

The audit's findings have immediate implications for regulators, researchers, and clinicians. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) increasingly require evidence of both durability and comparative effectiveness when considering new therapies for approval or reimbursement. The lack of trials meeting all TRIM Hypothesis 3 criteria means that current evidence may not suffice for claims of long-term superiority over traditional therapies.

For researchers, the audit provides a concrete roadmap for future trial design. To address these evidence gaps, new studies should incorporate active traditional therapy comparators, validated outcome measures, and extended controlled follow-up to at least 12 months. This is especially relevant as payers and health technology assessment bodies scrutinize the cost-effectiveness and real-world value of psychedelic-assisted interventions.

One non-obvious implication highlighted by the audit is that the absence of long-term, controlled comparator data may inadvertently bias the field toward overestimating the durability of psychedelic-assisted therapy effects. Without rigorous, head-to-head comparisons at extended time points, it is difficult to distinguish between sustained treatment effects and naturalistic symptom fluctuation or regression to the mean.

Risks, Unknowns, and Limitations

The main risk identified by the audit is the potential for premature or overstated claims about the long-term benefits of psychedelic-assisted therapy. Without robust, controlled data at 12 months or beyond, there remains significant uncertainty about the durability and comparative value of these interventions. This uncertainty may affect clinical guidelines, insurance coverage decisions, and patient expectations.

Additionally, the audit notes that some trials report uncontrolled follow-up data at 12 months or longer, but these do not meet the rigorous standard set by TRIM Hypothesis 3. Uncontrolled data are vulnerable to confounding factors such as spontaneous remission, concurrent treatments, or selective attrition, limiting their interpretability.

Finally, the audit itself is limited by the available literature as of November 2026. Ongoing and future studies may yet fill these gaps, but as of publication, no trial fully constitutes a test of TRIM Hypothesis 3 as originally specified.

Looking Forward: Designing Trials to Meet Emerging Standards

To advance the field, future RCTs of MDMA- and psilocybin-assisted therapy should prioritize the inclusion of active traditional therapy comparators, validated outcome scales, and extended controlled follow-up to at least 12 months. Such designs will be essential for meeting regulatory and payer standards, informing clinical practice, and accurately characterizing the comparative durability of psychedelic-assisted interventions.

As the field matures, systematic evidence audits like this one will play a crucial role in identifying methodological gaps and guiding the next generation of clinical research. Stakeholders—including trial sponsors, funders, and regulatory agencies—should consider these findings when developing protocols and setting evidence requirements for psychedelic-assisted therapies.

Reviewed by Dr. Alex Krieger, PhD (clinical trials methodology), November 2026. How we research: This analysis is based on a direct reading of the cited OpenAlex audit and cross-checked against primary trial registries and regulator documentation as of November 2026.